October 31, 2018 11:52 AM EDT

Tonix jumps on rejigged phase III for PTSD drug; MeiraGTx scores another NIH deal; OpGen, Qiagen join hands to detect superbugs

ENDPOINTS

→ After a Phase III trial testing its PTSD drug, Tonmya, involving patients that suffered trauma during military service since 2001, was prematurely halted following …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Tonix jumps on rejigged phase III for PTSD drug; MeiraGTx scores another NIH deal; OpGen, Qiagen join hands to detect superbugs

ENDPOINTS

Sign up to read this article for free.

Director Oligonucleotide R&D

Bachem

Bubendorf, BL, Switzerland

CBER's deputy director departs as staff shakeup continues

Bluebird bio to sell to investment funds after struggling to make money from gene therapies

Eli Lilly stockpiles $548M of oral weight loss drug ahead of launch

FDA approves first drug to treat ultra-rare lipid storage disease

Will CRISPR matter?

Trusted protection: Why the current meningococcal vaccination schedule shouldn’t change without strong evidence

Tonix jumps on re­jigged phase III for PTSD drug; MeiraGTx scores an­oth­er NIH deal; Op­Gen, Qi­a­gen join hands to de­tect su­per­bugs

Sign up to read this article for free.

Bachem

Bubendorf, BL, Switzerland

Tonix jumps on rejigged phase III for PTSD drug; MeiraGTx scores another NIH deal; OpGen, Qiagen join hands to detect superbugs